Biopharmaceutical Manufacturing Consortium (BioMaC)

The Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), intends to release a competitive solicitation entitled “Biopharmaceutical Manufacturing Consortium (BioMaC)” via SAM.gov on or about June 2023. BARDA plans to use its Other Transaction Authority under 42 USC Section 247d-7e(c)(5)(A). BARDA intends to solicit for a Consortium Management Firm (CMF) to coordinate with and manage a group of industry partners that will respond to requirements in one or more of the following biopharmaceutical manufacturing domains: Industrial Base Expansion of Biomanufacturing Supply Chain Biomanufacturing Capacity Expansion and Reservation Advanced Biomanufacturing Technologies Some examples of anticipated efforts under this planned consortium, subject to availability of funding, are manufacturing capacity expansion for Nucleoside Triphosphates (NTPs), BSL2 fill finish, and manufacturing of biologically derived small molecules. This notice in no way commits the Government to proceeding with any solicitation. This notice does not constitute a call for submissions or a promise to issue a call for submissions in the future. This notice does not commit the USG to contract for any supply or service whatsoever. Updates to the details provided could arise based on information and insight gained in the interim. Furthermore, BARDA is not at this time seeking proposals, and will not accept unsolicited proposals.